147 related articles for article (PubMed ID: 22738293)
1. Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
Flipo M; Willand N; Lecat-Guillet N; Hounsou C; Desroses M; Leroux F; Lens Z; Villeret V; Wohlkönig A; Wintjens R; Christophe T; Kyoung Jeon H; Locht C; Brodin P; Baulard AR; Déprez B
J Med Chem; 2012 Jul; 55(14):6391-402. PubMed ID: 22738293
[TBL] [Abstract][Full Text] [Related]
2. Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
Flipo M; Desroses M; Lecat-Guillet N; Villemagne B; Blondiaux N; Leroux F; Piveteau C; Mathys V; Flament MP; Siepmann J; Villeret V; Wohlkönig A; Wintjens R; Soror SH; Christophe T; Jeon HK; Locht C; Brodin P; Déprez B; Baulard AR; Willand N
J Med Chem; 2012 Jan; 55(1):68-83. PubMed ID: 22098589
[TBL] [Abstract][Full Text] [Related]
3. Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
Flipo M; Desroses M; Lecat-Guillet N; Dirié B; Carette X; Leroux F; Piveteau C; Demirkaya F; Lens Z; Rucktooa P; Villeret V; Christophe T; Jeon HK; Locht C; Brodin P; Déprez B; Baulard AR; Willand N
J Med Chem; 2011 Apr; 54(8):2994-3010. PubMed ID: 21417236
[TBL] [Abstract][Full Text] [Related]
4. Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
Nikiforov PO; Blaszczyk M; Surade S; Boshoff HI; Sajid A; Delorme V; Deboosere N; Brodin P; Baulard AR; Barry CE; Blundell TL; Abell C
ACS Chem Biol; 2017 May; 12(5):1390-1396. PubMed ID: 28314097
[TBL] [Abstract][Full Text] [Related]
5. Fragment-Based Optimized EthR Inhibitors with
Villemagne B; Machelart A; Tran NC; Flipo M; Moune M; Leroux F; Piveteau C; Wohlkönig A; Wintjens R; Li X; Gref R; Brodin P; Deprez B; Baulard AR; Willand N
ACS Infect Dis; 2020 Mar; 6(3):366-378. PubMed ID: 32011115
[TBL] [Abstract][Full Text] [Related]
6. Insights into mechanisms of induction and ligands recognition in the transcriptional repressor EthR from Mycobacterium tuberculosis.
Frénois F; Baulard AR; Villeret V
Tuberculosis (Edinb); 2006 Mar; 86(2):110-4. PubMed ID: 16243584
[TBL] [Abstract][Full Text] [Related]
7. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator.
Engohang-Ndong J; Baillat D; Aumercier M; Bellefontaine F; Besra GS; Locht C; Baulard AR
Mol Microbiol; 2004 Jan; 51(1):175-88. PubMed ID: 14651620
[TBL] [Abstract][Full Text] [Related]
8. Synthetic EthR inhibitors boost antituberculous activity of ethionamide.
Willand N; Dirié B; Carette X; Bifani P; Singhal A; Desroses M; Leroux F; Willery E; Mathys V; Déprez-Poulain R; Delcroix G; Frénois F; Aumercier M; Locht C; Villeret V; Déprez B; Baulard AR
Nat Med; 2009 May; 15(5):537-44. PubMed ID: 19412174
[TBL] [Abstract][Full Text] [Related]
9. Structural and docking studies of potent ethionamide boosters.
Tatum NJ; Villemagne B; Willand N; Deprez B; Liebeschuetz JW; Baulard AR; Pohl E
Acta Crystallogr C; 2013 Nov; 69(Pt 11):1243-50. PubMed ID: 24192167
[TBL] [Abstract][Full Text] [Related]
10. Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.
Villemagne B; Flipo M; Blondiaux N; Crauste C; Malaquin S; Leroux F; Piveteau C; Villeret V; Brodin P; Villoutreix BO; Sperandio O; Soror SH; Wohlkönig A; Wintjens R; Deprez B; Baulard AR; Willand N
J Med Chem; 2014 Jun; 57(11):4876-88. PubMed ID: 24818704
[TBL] [Abstract][Full Text] [Related]
11. New active leads for tuberculosis booster drugs by structure-based drug discovery.
Tatum NJ; Liebeschuetz JW; Cole JC; Frita R; Herledan A; Baulard AR; Willand N; Pohl E
Org Biomol Chem; 2017 Dec; 15(48):10245-10255. PubMed ID: 29182187
[TBL] [Abstract][Full Text] [Related]
12. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
Nikiforov PO; Surade S; Blaszczyk M; Delorme V; Brodin P; Baulard AR; Blundell TL; Abell C
Org Biomol Chem; 2016 Feb; 14(7):2318-26. PubMed ID: 26806381
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance.
Dover LG; Corsino PE; Daniels IR; Cocklin SL; Tatituri V; Besra GS; Fütterer K
J Mol Biol; 2004 Jul; 340(5):1095-105. PubMed ID: 15236969
[TBL] [Abstract][Full Text] [Related]
14. Exploring drug target flexibility using in situ click chemistry: application to a mycobacterial transcriptional regulator.
Willand N; Desroses M; Toto P; Dirié B; Lens Z; Villeret V; Rucktooa P; Locht C; Baulard A; Deprez B
ACS Chem Biol; 2010 Nov; 5(11):1007-13. PubMed ID: 20704273
[TBL] [Abstract][Full Text] [Related]
15. Unconventional surface plasmon resonance signals reveal quantitative inhibition of transcriptional repressor EthR by synthetic ligands.
Crauste C; Willand N; Villemagne B; Flipo M; Willery E; Carette X; Dimala MM; Drucbert AS; Danze PM; Deprez B; Baulard AR
Anal Biochem; 2014 May; 452():54-66. PubMed ID: 24561027
[TBL] [Abstract][Full Text] [Related]
16. The Mycobacterium tuberculosis transcriptional repressor EthR is negatively regulated by Serine/Threonine phosphorylation.
Leiba J; Carrère-Kremer S; Blondiaux N; Dimala MM; Wohlkönig A; Baulard A; Kremer L; Molle V
Biochem Biophys Res Commun; 2014 Apr; 446(4):1132-8. PubMed ID: 24667600
[TBL] [Abstract][Full Text] [Related]
17. Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis.
Prieri M; Frita R; Probst N; Sournia-Saquet A; Bourotte M; Déprez B; Baulard AR; Willand N
Eur J Med Chem; 2018 Nov; 159():35-46. PubMed ID: 30268015
[TBL] [Abstract][Full Text] [Related]
18. Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis.
Frénois F; Engohang-Ndong J; Locht C; Baulard AR; Villeret V
Mol Cell; 2004 Oct; 16(2):301-7. PubMed ID: 15494316
[TBL] [Abstract][Full Text] [Related]
19.
Sawicki R; Ginalska G
Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
[TBL] [Abstract][Full Text] [Related]
20. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
Christophe T; Ewann F; Jeon HK; Cechetto J; Brodin P
Future Med Chem; 2010 Aug; 2(8):1283-93. PubMed ID: 21426019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
